Back working full time in my Day JOB :(((. They need me :(( Sporadig trading for now
Followers | 141 |
Posts | 7,182 |
Boards Moderated | 1 |
Alias Born | 07/06/2006 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ABAT : L2 shows bid size of 55K at 1.2, 15K at 1.23 and 18K at 1.24 while all selling sizes at different level, the max is 14k minimum is 2K.
Possibly the flipper who shorted at 1.34 wants to cover at 1.2, that is some good profit, if I say so myself.
Why would I buy at 1.2 since I can buy it below dollar.
For weeks before the jump to 1.90, was a major resistant, and technically, major resistant become a strong support. So if it broke the1.10 then we will go below dollar, it will take days of fluctuation to achieve that, which is heaven for flippers and day traders.
Coz I am Long.
There is this stock I own, bought a year ago at 22 when it went to 33 I was very close in selling it, but my principle is once I do an extensive DD on a stock, I become long on it. Now that stock i is selling for $57 within 13 months of purchasing it.
Daily or monthly fluctuation is not important. Unless you are a day, swing, flipper trader.
Blue_xx: maybe, anyway I was in at 0.99. If it goes below that, I will add.
Strange though, the volume is not even a fraction of it's daily average or the past 8 days morning trading, for a sell off
I believe the bottom would be around 1.10 to 1.15.
$ABAT : asks is being wiped out.. what is going on.
Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
Date : 07/28/2011 @ 8:47AM
Source : PR Newswire
Stock : Soligenix, Inc. (SNGX)
Quote : 0.29 0.0 (0.00%) @ 7:07AM
http://ih.advfn.com/p.php?pid=nmona&article=48604934&symbol=SNGX
Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
Today : Thursday 28 July 2011
Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) for the development and commercialization of orBec® (oral beclomethasone dipropionate or Oral BDP) into the European territory.
As part of the amended agreement, Sigma-Tau has made a $5 million upfront payment to Soligenix. In addition, Sigma-Tau will make additional payments to Soligenix totaling $11 million, subject to the achievement of certain milestones. The first milestone, a $2 million payment, will be made upon the successful completion of the confirmatory Phase 3 clinical trial of orBec® for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD). Sigma-Tau will also pay Soligenix a 40% royalty on net sales pursuant to which Soligenix will supply the drug product while maintaining worldwide manufacturing rights. All commercialization expense in the European territory, including launch activities, will be borne by Sigma-Tau.
Ugo DiFrancecso, Chief Executive Officer of the Sigma-Tau Group which is headquartered in Rome, Italy, commented, "We are pleased to expand our partnership with Soligenix around orBec®. We remain optimistic about a near-term approval in the European market and the opportunity to bring our considerable expertise in the distribution of rare disease medicines to ensure that all GI GVHD patients throughout Europe will be able to access this important medicine."
"We expect the expanded Sigma-Tau collaboration will help us realize the full potential of orBec® and oral BDP in the treatment of GI GVHD and other inflammatory GI diseases," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "We now have an experienced commercialization partner in the second major world market and we are pleased with the robust royalty rates that we have garnered through this strong business relationship. There will also be significant economies of scale that we will realize through having one partner in both major territories. This partnership will provide for the launch and commercialization of orBec® in North America and Europe, without any further related expense to Soligenix or its shareholders. It also provides us with the potential for ongoing development funding across multiple indications for orBec® and oral BDP."
About orBec®
orBec®, oral beclomethasone dipropionate (oral BDP), is currently the subject of a confirmatory Phase 3 clinical trial in the treatment of acute GI GVHD. This Phase 3 trial, also referred to as the SUPPORTS protocol (Sparing Unnecessary Prednisone Phase 3 orBec® Randomized Treatment Study), will enroll an estimated 166 patients to confirm the clinically meaningful endpoints observed in previous Phase 2 and Phase 3 clinical studies. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value 0.005) in the Company's previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment). The SUPPORTS trial is being conducted at major transplant centers throughout the US, Europe, and Australia and is expected to complete in the second half of 2011. The trial is the subject of a Special Protocol Assessment (SPA) agreement that the Company reached with the US Food and Drug Administration (FDA).
orBec® was the subject of two prior randomized, double-blind, placebo-controlled clinical trials in acute GI GVHD. The first study was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139). At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, p-value 0.04).
orBec® represents a first-of-its-kind oral, locally acting therapy tailored to treat the GI manifestation of acute GVHD, the organ system where GVHD is most frequently encountered and highly problematic. orBec® is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD. orBec® is formulated for oral administration in GVHD patients as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract. Oral BDP may also have application in treating other GI disorders characterized by severe inflammation.
In addition to issued patents and pending worldwide patent applications, orBec® benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, as well as an orphan drug designation in the US for the prevention of acute GVHD and the treatment of chronic GI GVHD. Orphan drug designations provide for 7 and 10 years of market exclusivity upon approval in the US and Europe, respectively. orBec® has also received Fast Track designation from the FDA for the treatment of GI GVHD.
About GVHD
GVHD is a painful, debilitating and sometimes fatal disease. It is a common disorder among immunocompromised cancer patients after receiving allogeneic stem cell or bone marrow transplants. Unlike organ transplants where the patient's body may reject the organ, in GVHD it is the donor cells that begin to attack the patient's body – most frequently the gut, liver and skin. Patients with mild-to-moderate GI GVHD typically develop symptoms of anorexia, nausea, vomiting and diarrhea. If left untreated, GI GVHD can progress to ulcerations in the lining of the GI tract, and in its most severe form, can be fatal.
Systemic immunosuppressive agents such as prednisone, which are the current standard treatments for GVHD, are associated with high mortality rates due to infection and debility. Further, these drugs have not been approved for treating GVHD in the US or European Union, but rather are used off-label for this indication.
About the Sigma-Tau Group
The Sigma-Tau Group is a leading international pharmaceutical group with wholly Italian-owned capital that invests in the research, development and marketing of innovative and effective treatments to improve patient well-being and quality of life. Sigma-Tau was founded in Italy in 1957 and achieved global revenues of euro 673 million in 2010. Sigma-Tau Group has headquarters in Pomezia (Rome, Italy), and subsidiaries in France, Switzerland, the Netherlands, Belgium, Portugal, Germany, UK, India, US and Spain, these latter two with a production plant. It has over 2400 employees and an extensive network of licensees worldwide.
Sigma-Tau invests on average 16% of its revenue in R&D, and employs approximately 400 researchers currently working on its significant discovery pipeline, studying, through clinical and pre-clinical trials, 26 different molecules, mostly (11) new and original, and 18 owned by the Sigma-Tau Group. Therapeutic areas in which the company's research and development are focused include rare and neglected diseases, oncology, immunology and biotech. For more information about the Sigma-Tau Group visit: www.sigma-tau.it.
About Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. based in Gaithersburg, Maryland, is a wholly-owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases. Since 1989, the Company's products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers. With more than 7,000 identified rare diseases that affect approximately 25 million patients in the Unites States, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few. The Company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria, and other areas of unmet medical need. For more information about the company, visit www.sigmatau.com.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a $1.2 million FDA Orphan Products Grant-supported confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD. Soligenix is also conducting a National Cancer Institute (NCI)-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax™ is currently the subject of a $9.4 million NIAID grant supporting development of new heat stable vaccines. Soligenix is also developing SGX202 for the treatment of radiation injury and has recently released positive preliminary preclinical results in a canine gastrointestinal acute radiation syndrome model.
For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.
This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM™ are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
SOURCE Soligenix, Inc.
If Sheff sold anything he will mentioned it as an ALERT, so far no alert for SNGX or The other stock being sold
Columbia Laboratories Licenses STRIANT Canadian Trademark and Marketing Rights to Invaron Pharmaceuticals Inc.
Date : 07/27/2011 @ 6:50AM
Source : Business Wire
Stock : Columbia Laboratories, Inc. (CBRX)
Quote : 2.91 -0.12 (-3.96%) @ 3:35PM
http://ih.advfn.com/p.php?pid=nmona&article=48585509&symbol=CBRX
Columbia Laboratories Licenses STRIANT Canadian Trademark and Marketing Rights to Invaron Pharmaceuticals Inc.
Columbia labs (NASDAQ:CBRX)
Intraday Stock Chart
Today : Wednesday 27 July 2011
Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into a license agreement with Invaron Pharmaceuticals Inc. (“Invaron”), a privately-held Canadian pharmaceutical company, for STRIANT® (testosterone buccal system) in Canada.
Under the terms of the agreement, Invaron will seek regulatory approval for and will market STRIANT in Canada. Columbia will receive a royalty on annual net sales of STRIANT in Canada, assuming Invaron receives Health Canada regulatory approval. Revenues to Columbia are not expected to be material.
About Invaron
Invaron is a Canadian based pharmaceutical company focusing exclusively on the acquisition of niche drugs and medical devices registered in other countries but not in Canada. By facilitating local registration, bridging clinical gaps, and launching with innovative marketing strategies Invaron will effectively meet the under serviced needs of Canadian patients in a wide variety of therapeutic areas.
Invaron’s press releases and other company information are available online at www.invaron.ca. Invaron encourages patients, physicians, potential pharmaceutical partners and other stakeholders to visit www.invaron.ca/contact_us to request that Invaron examine the regulatory approval for a particular drug or medical device.
About Columbia Laboratories
Columbia Laboratories, Inc. is developing products that utilize its novel bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. The Company has developed and sold six products for the U.S. market including CRINONE® (progesterone gel), for which Columbia receives royalties on annual net sales from Watson Pharmaceuticals. CRINONE is commercialized outside the U.S. by Merck Serono. STRIANT® (testosterone buccal system) is marketed by Actient Pharmaceuticals (U.S.) and The Urology Company (Europe). The Company’s New Drug Application (NDA) for PROCHIEVE® (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy was accepted for filing by the Food and Drug Administration (FDA) with a PDUFA date of February 26, 2012.
Columbia's press releases and other company information are available online at www.columbialabs.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words “may,” “will,” “plans,” “believes,” “expects,” “anticipates,” “potential,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the outcome of further analyses by the FDA of the clinical data in the PROCHIEVE® NDA; success in obtaining timely approval of PROCHIEVE in the preterm birth indication by the FDA; the timing and level of success of a future product launch, if any; the ability of Columbia's third-party manufacturers to supply CRINONE®, PROCHIEVE and STRIANT; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; the ability to obtain and enforce patents and other intellectual property rights; the impact of competitive products and pricing; the timely and successful negotiation of partnerships or other transactions; the strength of the United States dollar relative to international currencies; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia’s reports filed with the SEC. Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein.
STRIANT® is a registered trademark of Actient Pharmaceuticals, LLC., in the U.S.
STRIANT® SR is a registered trademark of The Urology Company in the United Kingdom and the E.U.
CRINONE® and PROCHIEVE® are registered trademarks of Watson Pharmaceuticals, Inc.
Blue_xx: stop mentioning other stock symbols, repeatedly, In your posts, it is a violation of Ihub posting rules. A major one.
Focus7 : thank you, my friend for that ABAT YouTube link. It is Awesome.
Briboy: I will try, if I can remember it.EOM
I hope yor prediction is right, I need to reload.
OT: Oh man, please stop, I can't take it anymore ROFL. $CAK
Oh my days, was that English.EOM
When ALEX ANNOUNCES SALES, I'll be in hospital suffering from severe dementia. $ATWT
We don't need a pop, it will attract more flippers, we need a steady, slow and continous rise. With 2-4% weekly rise.
Continue Climbing Higher and Higher $ABAT:
A better title for the article, me think
At Advanced Battery Technologies, a maker of rechargeable polymer lithium-ion batteries, there is a bit of a surge going on that could turn into a run up; there seems to be enough ‘strength of support’ to suggest it. The stock was trading in the $0.80 range at the beginning of this month and is now trading in the $1.60 range, a three week gain of 100%. Good, the “Faithful” holding onto to this stock have regained some lost ground. A $10 million stock buy- back by the Company was key in its recent ascent. I think the shares are still ‘attractive’ even at their current price.
Link:
http://www.smallcapnetwork.com/Can-They-Continue-Climbing-Higher-and-Higher-ABAT-HEV-BAA/s/via/14/article/view/p/mid/1/id/101/
A healthy close is between 1.65 to 1.67
still it will be much better to close @ 1.70 -1.75 level to be ready for tom run.
Do you think that he is an insider.EOM
$LCI : Broadfin Capital more than Doubles Stake in Lannett Co. to 5.1%
Posted July 19, 2011
By Richard Rabicoff
http://newyork.citybizlist.com/18/2011/7/19/Broadfin-Capital-more-than-Doubles-Stake-in-Lannett-Co.-to-5.1--cbl.aspx
NEW YORK -- Broadfin Capital, LLC reported in an SEC filing that it owns 1,441,707 shares or 5.1 percent of the common stock of Lannett Company, Inc. (AMEX: LCI).
That more than doubles Broadfin's stake, which was 2.29 percent as of March 31, 2011. The firm's shares are worth $6.78 million at Lannett's Tuesday closing price of $4.70.
Lannett, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. The company is led Arthur Bedrosian, president and chief executive officer.
Broadfin is a New York hedge fund, founded by Kevin Kotler in 2005. He previously worked at Kevin's interest in medical technology goes back to his pre-med days at Furman Selz, UBS, ING, and The Galleon Group.
SEC filing: http://tinyurl.com/3l6po46
$ATWT : They want millions @0.0006, and your only giving them 36,150..
Common son ; >)
John PetersenComments (8323) in respond to a question about $ABAT:
The worst thing about hatchet-job blogs is that they scare away both investors and people like me who are reluctant to take a firm stand when the reliability of a company's SEC reports is called into question. Those kinds of allegations and accusations cut right to the heart of the reporting system and it would foolish for anybody to take a firm position based on anything other than first hand knowledge.
Until the hatchet articles started flying, ABAT was a favorite because its management seemed to have very tight cost control and an ability to put a product out the door at a good margin. At one point I remember observing that they were too cheap to be cool.
My sense is that the allegations of impropriety are a tempest in a teapot, but I can't say that I know they're a tempest in a teapot. If ABAT emerges from this mess with a clean slate, people will look at the current price as the deal of the decade. It just takes a lot of steel to make that leap of faith for $1 of downside and $5 to $10 of upside. 15 Jul, 09:44 AM0
Link:
http://seekingalpha.com/article/279577-the-lithium-ion-battery-glut-will-be-massive?source=kizur
$ABAT don't know which direction is supposed to go.EM
$1.12 Pre-Market. EOM.
I love the picture. EOM.
$ABAT : SeekingAlpha blogger apologies for being wrong
What a surprise.
Link:
http://seekingalpha.com/article/279577-the-lithium-ion-battery-glut-will-be-massive?source=kizur
Dr. Goldstein describes LibiGel and why women with menopause may be interested:
Link:
My friend just bought last Thursday 850K via Scottrade online with no restriction to buy online.
Companies Scheduled For 2011 GHS Conference :
Jul. 7, 2011 (Business Wire) -- Global Hunter Securities (GHS) today announced the line-up of presenting companies for its 2011 GHS Conference. More than 160 publicly traded Energy, China and Metals & Mining companies from around the world will be presenting to hundreds of attending institutional investors, as well as meeting with them one-on-one in a focused environment.
The conference will be held Monday, July 18 and Tuesday, July 19, at the InterContinental San Francisco, with a welcome reception on the night of July 17. More information about attending the GHS Conference can be found on GHS’ website http://www.ghsecurities.com.
Energy companies that will be presenting include:
Abraxas Petroleum Corp AXAS
ATP Oil & Gas Corporation ATPG
Atwood Oceanics, Inc. ATW
Callon Petroleum CPE
Camac Energy CAK
Comstock Resources CRK
Crimson Exploration Inc. CXPO
Cross Border Resources XBOR
LINK:
http://www.istockanalyst.com/business/news/5278750/global-hunter-securities-announces-more-than-160-presenting-companies-scheduled-for-2011-ghs-conference
Excellent Catty, just don't forget to take a profit, this time.
ATWT : 45,000 only. Pathetic. Funny way for a pink stock to trade.
Where are all the sellers that Deepman said are dumping their shares.
Just breath, and ignore fcsc for few months. GLTA
So, green or red, it doesn't matter with free shares.
The only ppl who are hurting here is the ones who entered late, or the ones who didn't trade pink stocks as it suppose too.
Enough said.
Same here, actually all my shares are free. It doesn't matter whatever direction it goes.
But for anyone who entered it late trying to make a quick profit is delusional.
GLTA
ZNSTATED, Lol, rolling on the floor. EOM.
Two similar articles : and both are bashing $ACAD
Link:
1) The Street : with author name
http://www.thestreet.com/story/11164655/1/acadia-pharmaceuticals-investing-with-no-safety-net.html?cm_ven=RSSFeed
2) Magic Diligence : no author name, possible copy and paste :)
http://www.magicdiligence.com/articles/acadia-pharmaceuticals-2011-06
Short intreats rose to 1.10%
http://www.dailyfinance.com/company/acadia-pharmaceuticals-inc/acad/nas/short-interest
ACADIA PHARMACEUTICALS INC Institutional Ownership:
http://www.dailyfinance.com/company/acadia-pharmaceuticals-inc/acad/nas/institutional-ownership